As obesity clinical trials evolve, there is a growing emphasis on how decentralisation and new technologies can play a role.

Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize ® liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid ...

As the obesity epidemic continues rising, many physicians recognize the urgent need for specialized training beyond ...

The KAER framework is designed to help primary care providers partner with older adults to engage in shared decision-making ...

A Carnegie Mellon University-led team of researchers has secured an award of up to $34.9 million(opens in new window) from ...

Updated European guidelines for metabolic dysfunction–associated steatotic liver disease stressed a higher risk in people ...

Parcel Health stands out as a key player in providing innovative packaging solutions for compounding pharmacies. Parcel Health's eco-friendly paper pill bottles ensure the stability and integrity of ...

The weight loss jab Mounjaro will soon be made available to nearly a quarter of a million NHS patients, according to ...

The $200B GLP-1 market is set to expand with 16 new obesity drugs launching by 2029, challenging Novo Nordisk and Eli Lilly's ...

Raising awareness about breast cancer encourages women to be proactive about regular check-ups and healthy habits, which are ...

Discover the growing demand for specialty training in obesity treatment as new options emerge. Learn about the current state and benefits of certification ...